Novo on Monday released full results from a late-stage trial showing its blockbuster Wegovy injection helped children ages 6 to under 12 with obesity shed weight, significantly lowering their body mass index.
Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks, with BMI falling 17.4% among children receiving the drug and rising 2.2% among those receiving a placebo. Those results assumed patients stayed on treatment during the trial.
When evaluating all children in the study, including those who discontinued treatment, Wegovy lowered BMI by an estimated average of 16.2 percentage points more than the placebo at 68 weeks. All 167 kids in the study received lifestyle modifications throughout the trial, including a reduced-calorie diet and increased physical activity.
The detailed results mark an encouraging step forward in treating childhood obesity — a chronic disease that can carry serious cardiovascular, metabolic and psychosocial consequences but has had few treatment options for younger children. When left unaddressed, childhood obesity can extend into adulthood, bringing earlier and more severe health complications.
"This is a very significant disease burden in this very young patient population," said Dr. Andrea Traina, Novo's medical director lead of obesity.